ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
June 27 2024 - 8:01AM
Business Wire
ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”)
(NASDAQ: IPA), an AI-driven biotherapeutic research and technology
company, is pleased to announce the appointment of Kristin Taylor
as Chief Financial Officer, effective immediately. Ms. Taylor has
been serving as Interim CFO since September 19th, 2023, and now
transitions into the role on a permanent basis.
Ms. Taylor is a seasoned financial executive with extensive
experience in both early-stage and large growth companies,
including those privately held, private equity-backed, and publicly
listed. She has a strong background in driving growth, establishing
infrastructure, and implementing effective strategies for value
creation in dynamic, scaling environments. Prior to joining IPA,
Ms. Taylor served as the Chief Financial Officer of Bay West LLC
and B-MoGen Biotechnologies Inc., along with capital markets and
liquidity management roles at Prime Therapeutics and Medtronic.
Previous to her corporate experience, she held technical and
consulting roles in public accounting. Her expertise spans growth
strategies and execution, fundraising and recapitalizations, due
diligence and acquisition integration, financial analysis,
accounting, audit and tax compliance, staff leadership and
development, process development and IT initiatives, and board and
investor relations.
Ms. Taylor holds an MBA in Finance and Strategic Management from
the Carlson School of Management at the University of Minnesota,
where she was a Carlson Scholar, and a Bachelor of Science in
Business Administration with a Major in Accounting and a Minor in
Communications. She is also a Certified Public Accountant
(inactive).
“We are thrilled to welcome Kristin to ImmunoPrecise as our new
CFO,” said Jennifer Bath, CEO of IPA. “Her extensive experience and
proven track record in financial leadership will be invaluable as
we continue to drive our growth and strategic initiatives forward.
Her performance during her interim tenure has been exemplary, and
we are confident in her ability to lead our financial
operations.”
About ImmunoPrecise Antibodies Ltd.
The IPA Family is a biotherapeutic research and technology group
that leverages systems biology, multi-omics modelling and complex
artificial intelligence systems to support its proprietary
technologies in bioplatform-based antibody discovery. Services
include highly specialized, full-continuum therapeutic biologics
discovery, development, and out-licensing to support its business
partners in their quest to discover and develop novel biologics
against the most challenging targets. ImmunoPrecise Antibodies Ltd.
has several subsidiaries in North America and Europe including
entities such as Talem Therapeutics LLC, BioStrand BV,
ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies
(Europe) B.V. (collectively, the “IPA Family”). For further
information, visit www.ipatherapeutics.com.
Source: ImmunoPrecise Antibodies Ltd.
Forward-Looking Statement:
This press release contains forward-looking statements, which
are based on current expectations and involve risks and
uncertainties. These statements include our expectations regarding
Kristin Taylor’s impact as Chief Financial Officer and our future
growth and financial performance.
Factors that could cause actual results to differ include
economic conditions, regulatory changes, and other risks detailed
in our filings with securities regulators in the United States and
Canada. We do not undertake any obligation to update these
forward-looking statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627304070/en/
Investor contact: investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From May 2024 to Jun 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Jun 2023 to Jun 2024